BIOFRONTERA AG (BFRA) Stock Price & Overview
NASDAQ:BFRA
The current stock price of BFRA is 2.67 null. Today BFRA is down by -9.49%. In the past month the price decreased by -6.97%. In the past year, price decreased by -55.35%.
BFRA Key Statistics
- Market Cap
- 151.435M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.29
- Dividend Yield
- N/A
BFRA Stock Performance
BFRA Stock Chart
BFRA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BFRA. When comparing the yearly performance of all stocks, BFRA is a bad performer in the overall market: 84.4% of all stocks are doing better.
BFRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BFRA. BFRA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BFRA Earnings
BFRA Forecast & Estimates
5 analysts have analysed BFRA and the average price target is 14.22 null. This implies a price increase of 432.69% is expected in the next year compared to the current price of 2.67.
For the next year, analysts expect an EPS growth of -137.77% and a revenue growth -5.25% for BFRA
BFRA Groups
Sector & Classification
BFRA Financial Highlights
Over the last trailing twelve months BFRA reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 23.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -55.98% | ||
| ROA | -22.64% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
BFRA Ownership
BFRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.38 | 401.392B | ||
| AMGN | AMGEN INC | 16.54 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.84 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.64 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.87 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.98 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.04 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BFRA
Company Profile
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 167 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Company Info
IPO: 2006-10-30
BIOFRONTERA AG
Hemmelrather Weg 201
Leverkusen NORDRHEIN-WESTFALEN D-51377 DE
CEO: Hermann Lubbert
Employees: 167
Phone: 49214876320.0
BIOFRONTERA AG / BFRA FAQ
What does BIOFRONTERA AG do?
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 167 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
What is the stock price of BIOFRONTERA AG today?
The current stock price of BFRA is 2.67 null. The price decreased by -9.49% in the last trading session.
Does BFRA stock pay dividends?
BFRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BFRA stock?
BFRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for BFRA stock?
The Revenue of BIOFRONTERA AG (BFRA) is expected to decline by -5.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for BFRA stock?
You can find the ownership structure of BIOFRONTERA AG (BFRA) on the Ownership tab.